The U.S. Food and Drug Administration is expediting the review process for Francis Medical’s prostate cancer therapy technology, a process that happens when a new treatment is more effective than current standards of care.
The U.S. Food and Drug Administration is expediting the review process for Francis Medical’s prostate cancer therapy technology, a process that happens when a new treatment is more effective than current standards of care.
